多西紫杉醇联合顺铂2周方案治疗晚期非小细胞肺癌临床观察

Two-week docetaxel plus cisplatin in the treatment of advanced non-small-cell lung cancer.

目的探讨多西紫杉醇联合顺铂2周给药一线治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副作用。方法多西紫杉醇75mg/m2静脉滴注,顺铂25mg/m2×3d静脉滴注联合化疗,每2周重复疗程。化疗期间用粒细胞-集落刺激因子预防性支持治疗。结果共39例晚期NSCLC患者完成化疗,36例可评价疗效,其中完全缓解1例(2.8%),部分缓解13例(36.1%),稳定21例(58.3%),进展1例(2.8%);总有效率38.9%。本方案化疗所致毒性反应主要为骨髓抑制,恶心、呕吐,肌肉、关节痛,脱发和疲劳。结论多西紫杉醇联合顺铂2周给药是治疗晚期NSCLC的有效可行方案,其毒副作用患者可耐受,值得进一步研究。

Objective To evaluate the efficacy and toxicity of docetaxel plus cisplatin given every 2 weeks in advanced non-small-cell lung cancer （ NSCLC ）. Methods 75 mg/m^2 docetaxel combined with 25 mg/m^2 cisplatin were administered intravenously for 3 days. Chemotherapy was performed every 2 weeks with prophylactic use of granulocyte colony-stimulating factor （ G-CSF ）. Results 39 cases with advanced NSCLC received chemotherapy. 36 cases were evaluated,of whom 1 case completely relieved （2.8%） ,13 cases partially relieved （36.1%） ,21 cases were stable （58.3%） and 1 case developed （2.8%） ,with the overall response rate of 38.9%. The major toxicity included myelosuppression, nausea and vomiting, alopeeia, myalgia and arthralgia and fatigue. Conclusion The two-week combination chemotherapy of docetaxel and cisplatin is feasible and effective for patients with advanced NSCLC. The toxicity of this regimen is well tolerated.